Assembly Biosciences (ASMB) Hits New 12-Month Low at $13.13

Share on StockTwits

Assembly Biosciences Inc (NASDAQ:ASMB) reached a new 52-week low during trading on Monday . The company traded as low as $13.13 and last traded at $14.80, with a volume of 81780 shares traded. The stock had previously closed at $18.79.

ASMB has been the subject of a number of research analyst reports. BidaskClub raised shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research report on Tuesday, January 1st. Chardan Capital reaffirmed a “hold” rating and issued a $30.00 target price on shares of Assembly Biosciences in a research report on Monday. Finally, Zacks Investment Research raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a research report on Thursday, February 21st. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $43.00.

The stock has a market capitalization of $500.77 million, a P/E ratio of -3.71 and a beta of 1.75.

Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Thursday, February 28th. The biopharmaceutical company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.12). Assembly Biosciences had a negative return on equity of 57.48% and a negative net margin of 613.02%. The company had revenue of $3.74 million during the quarter, compared to the consensus estimate of $3.69 million. On average, research analysts predict that Assembly Biosciences Inc will post -4.61 EPS for the current year.

Large investors have recently bought and sold shares of the business. Legal & General Group Plc grew its position in shares of Assembly Biosciences by 23.0% during the 3rd quarter. Legal & General Group Plc now owns 3,289 shares of the biopharmaceutical company’s stock valued at $122,000 after acquiring an additional 616 shares during the period. Metropolitan Life Insurance Co. NY grew its position in shares of Assembly Biosciences by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,073 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 5,524 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of Assembly Biosciences during the 3rd quarter valued at $407,000. BlueMountain Capital Management LLC grew its position in shares of Assembly Biosciences by 100.3% during the 3rd quarter. BlueMountain Capital Management LLC now owns 14,601 shares of the biopharmaceutical company’s stock valued at $542,000 after acquiring an additional 7,313 shares during the period. Finally, Two Sigma Investments LP bought a new stake in shares of Assembly Biosciences during the 4th quarter valued at $336,000. 83.62% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Week Herald and is the property of of Week Herald. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://weekherald.com/2019/04/15/assembly-biosciences-asmb-hits-new-12-month-low-at-13-13.html.

About Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Further Reading: Market Capitalization – What it Means for Investors

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.